Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.

Kohei ShigetaAya MatsuiHiroto KikuchiSebastian KleinEmilie MamessierIvy X ChenShuichi AokiShuji KitaharaKoetsu InoueAyako ShigetaTai HatoRakesh R RamjiawanDaniel StaiculescuDieter ZopfLukas FiebigGabriela S HobbsAlexander QuaasSimona DimaIrinel PopescuPeigen HuangLance L MunnMark CobboldLipika GoyalAndrew X ZhuRakesh K JainDan G Duda

Published in: Journal for immunotherapy of cancer (2021)

Judicious regorafenib/anti-PD1 combination therapy can inhibit tumor growth and increase survival by normalizing tumor vasculature and increasing intratumoral CXCR3+CD8 T-cell infiltration through elevated CXCL10 expression in HCC cells.

Keyphrases

combination therapy
poor prognosis
induced apoptosis
metastatic colorectal cancer
cell cycle arrest
long non coding rna
cell proliferation
cell death